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Abstract: Introduction: Febrile neutropenic patients are at risk of serious infections. The aim of the present study is
to identify the frequency, species, and susceptibility patterns of candidemia in febrile neutropenic patients.
Methods: This cross-sectional study was conducted on febrile neutropenic patients suspected with candidemia
who had been referred to 3 educational hospitals during 9 months. Results: The blood samples of 80 febrile
neutropenic patients with the mean age of 48±16.6 years were studied (60% female). Five (6.25%) episodes
of candidemia were identified. The underlying disease was acute myeloid leukemia in 4 (80%) cases and all
5(100%) cases had central venous catheter and were receiving prophylactic ciprofloxacin and acyclovir. 100%
of isolates were found to be susceptible to Voriconazole, 80% to Caspofungin, 60% to Amphotericin B, and 40%
to Fluconazole. Conclusion: The frequency of candidemia among the studied febrile neutropenia patients was
6.25%, with 80% mortality rate, and the most frequently identified yeast was Candida albicans (100% susceptible
to Voriconazole).
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1. Introduction
F
ebrile neutropenic patients are at risk of serious infec-
tions (1). Generally, bacteria are responsible for blood-
stream infections (BSIs), but, 8% of all cases of infec-
tious agents are Candida spp. (2, 3). Candida spp. that cause
candidemia are the fourth most common agent of BSIs and
the fifth most common cause of nosocomial infection (4, 5).
Candida albicans is the most important cause of BSIs; how-
ever 45% are caused by non-albicans species such as Candida
glabrata, Candida krusei, Candida parapsilosis, and Candida
tropicalis (6, 7).
It appears that infection caused by species of Candida is as-
sociated with a high crude mortality rate, globally (40% in the
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United States)(8). The epidemiology of candidemia has been
extensively studied in developed countries, but there is a lack
of data in developing ones. The aim of the present study is to
identify the frequency, species, and susceptibility patterns of
candidemia in febrile neutropenic patients.
2. Methods
2.1. Study design and setting
This cross-sectional study was conducted on febrile neu-
tropenic patients who had been referred to Khatam-al-
Anbia, Shohadaye Tajrish, and Taleghani educational hos-
pitals, Tehran, Iran, from November 2016 to August 2017.
The Ethical Committee of Shahid Beheshti University of
Medical Sciences approved this study under the code:
IR.SBMU.RETECH.REC.1396.192. All enrolled participants
were informed about the study and written informed consent
was obtained from them.
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2.2. Participants
Febrile neutropenic patients suspected of candidemia (based
on clinical symptoms), referred to emergency departments
or hospitalized in intensive care units (9) of the mentioned
hospitals were enrolled to the study. Patients who had pro-
longed fever in spite of receiving broad-spectrum antibiotics
for more than four days were considered as suspicious to
candidemia. Patients with chronic neutropenia were ex-
cluded from this study since the incidence of neutropenia is
unpredictable, and difficult to clearly identify and determine.
There was not any sex or age limitation.
2.3. Data gathering
Demographic and clinical data were collected including
age, sex, duration of stay in ICU, current history of broad-
spectrum antibiotic therapy (for > 4 days), antifungal ther-
apy, underlying diseases, and outcomes of sur–gical proce-
dures. Source of data was the patient’s profile. An Assistant
professor of infectious diseases (Dr. Yousefi) was responsi-
ble for selecting suspected cases. Neutropenia was defined as
neutrophil count <500/mm3 or <1000/mm3 with a predicted
decrease to <500/mm3 and fever was defined as single eleva-
tion in oral temperature to ≥ 38.30 ◦C or a temperature of ≥
38 ÂřC for ≥ 1 hour (10).
2.4. Cultures
10 ml of venous blood sample were obtained for each pa-
tient aseptically via venipuncture according to a standard
technique by using a sterile syringe after skin disinfection.
Culture vials were placed in the BACTEC 9120 System (Bec-
ton Dickinson Microbiology Systems, Maryland, DE, USA),
and were controlled automatically every 10 minutes. The
BACTEC bottles that showed a sign of fungal growth were
sub-cultured on the plates with the BHI agar (Merck, Ger-
many) and Sabouraud Dextrose Agar with Chloramphenicol
(SC) (Merck, Germany), separately. CHROM agar Candida
medium (CHROM agar Microbiology, Paris, France) was used
for sub-culture of isolates, incubated at 35 ◦C for 48 h and
for preliminary species identification, production of specific
colony colors were analyzed. ITS1 and ITS4 universal primers
were used for polymerase chain reaction (PCR) and DNA se-
quencing was also performed.
2.5. Susceptibility testing
In vitro antifungal susceptibility test of the Candida iso–lates
against amphotericin B (AMB) (Sigma-Aldrich, USA.), flu-
conazole (FLU) (Sigma-Aldrich, USA.), voriconazole (VOR)
(Pfizer Central Research, UK), and caspofungin (CAS) (Merck,
USA.) were performed using micro-dilution method.
2.6. Statistical analysis
Statistical analyses were performed using SPSS software ver-
sion 21.0. The findings were reported using descriptive statis-
tics such as mean ± standard deviation or frequency and per-
centage.
3. Results:
153 blood samples were collected from 80 febrile neu-
tropenic patients (38 blood samples from emergency depart-
ments and 115 from ICUs). The mean age of the patients was
48±16.6 years (60% female).
Five (6.25%) episodes of candidemia were identified during
the study period. Baseline characteristics and outcome of
patients with positive blood Culture are summarized in ta-
ble 1. The underlying disease was acute myeloid leukemia
in 4 (80%) cases and all 5(100%) cases had central venous
catheter and were receiving prophylactic ciprofloxacin and
acyclovir. The mean dura-tion of hospital and ICU stay in
patients with candidemia were 42±5.4 and 26±4.9 days, re-
spectively.
Table 2 shows the in vitro susceptibility of 5 Candida spp.
strains against antifungal agents. 100% of isolates were found
to be susceptible to Voriconazole, 80% to Caspofungin, 60%
to Amphotericin B, and 40% to Fluconazole.
4. Discussion
Based on the findings, the frequency of candidemia among
the studied febrile neutropenia patients was 6.25%, with 80%
mortality rate, and the most frequently identified yeast was
Candida albicans (100% susceptible to Voriconazole).
The fourth most common pathogen isolated from the blood
of ICU patients is Candida albicans, with an attributed mor-
tality range between 20–30%. (11-13). However, during re-
cent years, the incidence of Candida spp. infections other
than Candida albicans has significantly increased and Can-
dida parapsilosis is currently one of the main causes of inva-
sive candidiasis (14-16).
The estimated rate of candidemia among ICU admitted pa-
tients is between 0.5–32 cases per 1,000 admissions (17, 18).
Ghahri et al. identified Candida parapsilosis as the most
prevalent Candida spp. from the blood samples of patients
with candidemia in Iran; but this was not the case in our
study (14).
According to antifungal susceptibility tests, the most active
antifungal drug in isolated candida species was VOR; this re-
sult was similar to a study by Labbe et al. (19).
A study by Pfaller et al. on in vitro susceptibility results for
1,184 isolates showed that VOR was considerably more po-
tent than FLU (4). We also found similar results showing that
100% of candida isolates were sensitive to VOR.
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Table 1: Baseline characteristics and outcome of patients with positive blood Culture
Variables Case 1 Case 2 Case 3 Case 4 Case 5
Sex Female Female Female Male Male
Age (year) 61 34 26 48 71
Hospitalization (day) 44 50 34 43 38
ICU admission (day) 28 35 23 24 21
Underlying disease AML AML AML AML ALL
Prophylaxis
Ciprofloxacin + + + + +
Acyclovir + + + + +
Fluconazole + – + – +
Itraconazole – + – + –
Co-trimoxazole – – – – +
Medical device CVC CVC CVC CVC MV, CVC
Candida Spp. C. albicans C. albicans C. albicans C. albicans C. glabrata
Outcome Died Died Survived Died Died
ICU: intensive care unit; CVC: central venous catheter; MV: mechanical ventilation; ALL: acute lymphoblastic
leukemia; AML: acute myeloid leukemia.
Table 2: In vitro susceptibility test results of the 5 Candida spp. strains against 4 antifungal agents.
Antifungal agent Susceptible Dose dependent Resistant
Fluconazole 2 (40) 3 (60) 0 (0)
Voriconazole 5 (100) 0 (0) 0 (0)
Amphotericin B 3 (60) 1 (20) 1 (20)
Caspofungin 4 (80) 0 (0) 1 (20)
Data were reported as number (%).
This investigation showed that FLU has the highest MIC GM
(2.3); this result is similar to the study by Lobbe et al. that re-
ported the highest MIC for FLU compared to other azole an-
tifungal drugs such as VOR, ravuconazole, itraconazole, and
posaconazole (19).
A study by Pappas PG et al. proposed that in patients with
positive blood cultures that become positive more than 48
hours after collection, FLU should probably be avoided; and
it is more likely that patients are infected by Candida glabrata
(20).
A delay of ≥12 hours in the initial empiric antifungal treat-
ment was associated with higher hospital mortality (21). It
seems that empiric antifungal therapy needs to be started
early in order to decrease morbidity and mortality.
5. Limitations
This study had several limitations including the short dura-
tion of survey followed by a low number of positive patients.
Therefore, it was difficult to compare and interpret the find-
ings, especially antifungal susceptibility patterns. However,
based on the findings of this study, candidemia should be
considered a significant problem in febrile neutropenic pa-
tients.
6. Conclusion
Based on the finding, the frequency of candidemia among
the studied febrile neutropenia patients was 6.25%, with 80%
mortality rate, and the most frequently identified yeast was
Candida albicans (100% susceptible to Voriconazole).
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